JP2017535536A5 - - Google Patents

Download PDF

Info

Publication number
JP2017535536A5
JP2017535536A5 JP2017522120A JP2017522120A JP2017535536A5 JP 2017535536 A5 JP2017535536 A5 JP 2017535536A5 JP 2017522120 A JP2017522120 A JP 2017522120A JP 2017522120 A JP2017522120 A JP 2017522120A JP 2017535536 A5 JP2017535536 A5 JP 2017535536A5
Authority
JP
Japan
Prior art keywords
carbazole
carboxamide
fluoro
tetrahydro
hydroxypropan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017522120A
Other languages
English (en)
Japanese (ja)
Other versions
JP6599983B2 (ja
JP2017535536A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/057077 external-priority patent/WO2016065236A1/en
Publication of JP2017535536A publication Critical patent/JP2017535536A/ja
Publication of JP2017535536A5 publication Critical patent/JP2017535536A5/ja
Application granted granted Critical
Publication of JP6599983B2 publication Critical patent/JP6599983B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017522120A 2014-10-24 2015-10-23 カルバゾール誘導体 Active JP6599983B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462068234P 2014-10-24 2014-10-24
US62/068,234 2014-10-24
PCT/US2015/057077 WO2016065236A1 (en) 2014-10-24 2015-10-23 Carbazole derivatives

Publications (3)

Publication Number Publication Date
JP2017535536A JP2017535536A (ja) 2017-11-30
JP2017535536A5 true JP2017535536A5 (enExample) 2018-11-08
JP6599983B2 JP6599983B2 (ja) 2019-10-30

Family

ID=54427879

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017522120A Active JP6599983B2 (ja) 2014-10-24 2015-10-23 カルバゾール誘導体

Country Status (34)

Country Link
US (3) US10266491B2 (enExample)
EP (1) EP3209651B9 (enExample)
JP (1) JP6599983B2 (enExample)
KR (1) KR102514914B1 (enExample)
CN (1) CN107074804B (enExample)
AR (1) AR102427A1 (enExample)
AU (1) AU2015335703B2 (enExample)
BR (1) BR112017007545A2 (enExample)
CA (1) CA2965523A1 (enExample)
CL (1) CL2017001001A1 (enExample)
CO (1) CO2017004517A2 (enExample)
CY (1) CY1122549T1 (enExample)
DK (1) DK3209651T3 (enExample)
EA (1) EA032361B1 (enExample)
ES (1) ES2761903T3 (enExample)
HR (1) HRP20192197T2 (enExample)
HU (1) HUE048321T2 (enExample)
IL (1) IL251798B (enExample)
LT (1) LT3209651T (enExample)
MA (1) MA40302B1 (enExample)
ME (1) ME03754B (enExample)
MX (1) MX374724B (enExample)
MY (1) MY190568A (enExample)
PE (1) PE20171239A1 (enExample)
PH (1) PH12017500724B1 (enExample)
PL (1) PL3209651T3 (enExample)
PT (1) PT3209651T (enExample)
RS (1) RS59707B1 (enExample)
SG (2) SG10201903619YA (enExample)
SI (1) SI3209651T1 (enExample)
SM (1) SMT202000035T1 (enExample)
TN (1) TN2017000158A1 (enExample)
TW (1) TWI676618B (enExample)
WO (1) WO2016065236A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA121871C2 (uk) 2014-10-24 2020-08-10 Такеда Фармасьютікал Компані Лімітед Гетероциклічна сполука
AU2015335783B2 (en) * 2014-10-24 2019-10-03 Bristol-Myers Squibb Company Tricyclic atropisomer compounds
CN109153680B (zh) * 2016-07-07 2021-04-23 株式会社大熊制药 4-氨基吡唑并[3,4-d]嘧啶基氮杂双环衍生物及含其的药物组合物
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
US10807951B2 (en) 2017-10-13 2020-10-20 The Regents Of The University Of California mTORC1 modulators
CN109053542A (zh) * 2018-07-25 2018-12-21 南通大学 一种6-溴-5-羟基异吲哚啉-1-酮的化学合成方法
ES2965164T3 (es) * 2019-10-04 2024-04-11 Bristol Myers Squibb Co Compuestos de carbazol sustituidos
CN110862396B (zh) * 2019-11-29 2021-06-04 浙江工业大学 一种吡咯并[3,4-c]咔唑-1,3(2H,6H)-二酮类化合物的合成方法
WO2021207549A1 (en) * 2020-04-10 2021-10-14 Gb005, Inc. Kinase inhibitors
US12448363B2 (en) 2020-06-02 2025-10-21 Vidya Therapeutics, Inc. Kinase inhibitors
CN115232061B (zh) * 2021-09-18 2024-01-30 山西紫罗蓝新材料科技有限公司 一种3-硝基-9-乙基咔唑粗产物的提取工艺
PE20250844A1 (es) * 2022-07-06 2025-03-21 Vividion Therapeutics Inc Composiciones farmaceuticas que comprenden inhibidores de helicasa wrn
CA3268880A1 (en) * 2022-09-29 2024-04-04 Vividion Therapeutics, Inc. N-ACRYLOYLMORPHOLINE DERIVATIVES USED AS KEAP1 MODULATORS AND RELATED USES

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
CA2140722A1 (en) 1994-01-24 1995-07-25 Joseph A. Jakubowski Beta-carboline thromboxane synthase inhibitors
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
US7393848B2 (en) 2003-06-30 2008-07-01 Cgi Pharmaceuticals, Inc. Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds
WO2005047290A2 (en) 2003-11-11 2005-05-26 Cellular Genomics Inc. Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors
WO2006044687A2 (en) 2004-10-15 2006-04-27 Takeda San Diego, Inc. Kinase inhibitors
SG159549A1 (en) 2004-11-10 2010-03-30 Cgi Pharmaceuticals Inc Imidazo[1,2-a] pyrazin-8-ylamines useful as modulators of kinase activity
PL1831227T3 (pl) 2004-12-17 2013-10-31 Glenmark Pharmaceuticals Sa Nowe związki heterocykliczne użyteczne w leczeniu stanów zapalnych i dolegliwości alergicznych
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
ES2390135T3 (es) 2005-11-22 2012-11-06 Merck Sharp & Dohme Corp. Compuestos tricíclicos útiles como inhibidores de quinasas
JP2010502751A (ja) 2006-09-11 2010-01-28 シージーアイ ファーマシューティカルズ,インコーポレイティド キナーゼ阻害物質、およびキナーゼ阻害物質の使用および同定方法
CA2663178C (en) 2006-09-11 2016-01-12 Matrix Laboratories Ltd. Dibenzofuran derivatives as inhibitors of pde-4 and pde-10
US20090062251A1 (en) 2007-08-17 2009-03-05 Astrazeneca Ab Novel Compounds 002
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
US8431569B2 (en) * 2007-12-13 2013-04-30 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
US20110046378A1 (en) 2008-02-14 2011-02-24 Siemens Medical Solutions Usa, Inc. Novel Imaging Agents for Detecting Neurological Dysfunction
GB0809360D0 (en) 2008-05-22 2008-07-02 Isis Innovation Calcium modulation
TW201010997A (en) 2008-06-18 2010-03-16 Pfizer Ltd Nicotinamide derivatives
TWI546290B (zh) 2008-06-27 2016-08-21 賽基艾維洛米斯研究股份有限公司 雜芳基化合物及其用途
EP2151441A1 (en) 2008-08-06 2010-02-10 Julius-Maximilians-Universität Würzburg Beta-carbolin-derivates as substrates for an enzyme
PE20110819A1 (es) * 2008-12-19 2011-11-02 Bristol Myers Squibb Co Compuestos de carbazol carboxamida utiles como inhibidores de cinasa
CN101475571B (zh) 2009-01-21 2011-06-22 中国药科大学 β-咔啉类细胞周期蛋白依赖性激酶2抑制剂及其用途
ES2733093T3 (es) 2009-02-13 2019-11-27 Nextivity Inc Control remoto para amplificador
US8685969B2 (en) 2010-06-16 2014-04-01 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
EP2455378A1 (en) 2010-11-03 2012-05-23 Philip Morris Products S.A. Carbazole and carboline derivatives, and preparation and therapeutic applications thereof
AU2011330850B2 (en) 2010-11-15 2016-01-28 Viiv Healthcare Uk Limited Inhibitors of HIV replication
WO2012156334A1 (en) 2011-05-17 2012-11-22 F. Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
AU2013207972B2 (en) 2012-01-10 2017-06-15 Nimbus Iris, Inc. IRAK inhibitors and uses thereof
RU2619465C2 (ru) 2012-10-26 2017-05-16 Ф. Хоффманн-Ля Рош Аг Ингибиторы тирозинкиназы брутона
AU2014302550A1 (en) * 2013-06-25 2016-02-11 Bristol-Myers Squibb Company Carbazole carboxamide compounds useful as kinase inhibitors
AR096721A1 (es) * 2013-06-25 2016-01-27 Bristol Myers Squibb Co Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos
LT3461821T (lt) 2014-10-24 2020-08-10 Bristol-Myers Squibb Company Indolo karboksamido junginiai, naudotini kaip kinazės inhibitoriai
AU2015335783B2 (en) * 2014-10-24 2019-10-03 Bristol-Myers Squibb Company Tricyclic atropisomer compounds

Similar Documents

Publication Publication Date Title
JP2017535536A5 (enExample)
ME03754B (me) Derivaтi karbazola
AU2004223827B2 (en) Heterocyclic compounds and methods of use
ES2310758T3 (es) Derivados de isoquinolina sustituidos y metodos de uso.
KR101140474B1 (ko) 간세포 성장 인자 수용체의 억제제로서 유용한 융합된 헤테로시클릭 유도체 및 사용 방법
CN114948963B (zh) 蛋白激酶抑制剂苯并内酰胺化合物
KR101404290B1 (ko) 과다-증식성 장애 및 맥관형성과 관련된 질환을 치료하는데유용한 치환된 4-아미노-피롤로트리아진 유도체
EP1802586B1 (en) Heteroaryl-substituted alkyne compounds and method of use
ES2644873T3 (es) Derivados de 6-([1,2,4]triazolo[4,3-a]piridin-3-ilmetil)-1,6-naftiridin-5(6H)-ona como inhibidores de c-Met
ES2260277T3 (es) Compuestos de urea y sus procedimientos de utilizacion.
EP1971604B1 (en) Pyrrolo-pyridine derivatives for the treatment of cancer diseases
JP2017510576A5 (enExample)
RU2018123779A (ru) Новые соединения
JP2013520407A5 (enExample)
JP2020510092A5 (enExample)
JP2018507861A5 (enExample)
JP2016538316A5 (enExample)
EP2920177A1 (en) Compounds and compositions for the treatment of parasitic diseases
JP2005526029A (ja) 細胞増殖が関与する疾患を治療するためのキノリノン誘導体
AU2003256481A1 (en) Substituted anthranilic amide derivatives and methods of use
AU2003252011A1 (en) Substituted 2-alkylamine nicotinic amide derivatives and use there of
EA025520B1 (ru) N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
MXPA06001923A (es) Derivados de 2,3-dihidro-1h-isoindol-1-ona sustituidos y metodos de uso.
CN104602692A (zh) 作为激酶抑制剂的氨基喹啉
JP2018518522A5 (enExample)